(CercleFinance.com) – Novartis announced today that it has completed the acquisition of Chinook Therapeutics, a Seattle-based biopharmaceutical company specializing in the discovery, development and commercialization of precision drugs for kidney disease, as part of of a transaction valued at $3.5 billion.
Chinook’s pipeline includes two actives (atrasentan and zigakibart) in late-stage clinical development to treat immunoglobulin A nephropathy, as well as early-stage research and development programs.
Atrasentan is also in early-stage development for other rare kidney diseases, and Zigakibart entered phase 3 development in July 2023.
“We are delighted to complete this important transaction and look forward to leveraging our combined resources and expertise to advance the development of these promising treatments for the benefit of patients with rare and serious chronic kidney diseases,” said Vas Narasimhan. , director of Novartis.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
